Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ).
Lumos Diagnostics Holdings Ltd has issued 140,527 fully paid ordinary shares following the exercise of unquoted options by its employees. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant legal provisions, indicating transparency and adherence to regulatory standards.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.
Average Trading Volume: 6,662,202
Technical Sentiment Signal: Buy
Current Market Cap: A$102.7M
For a thorough assessment of LDX stock, go to TipRanks’ Stock Analysis page.